Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and CashPRNewsWire • 02/28/22
Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarketMarket Watch • 02/28/22
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio wiPRNewsWire • 02/28/22
Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022PRNewsWire • 02/04/22
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye DiseasePRNewsWire • 02/03/22
Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label RisksBenzinga • 01/20/22